Oral PHA121 May Lead to Faster, More Durable Effects Than Firazyr

Oral PHA121 May Lead to Faster, More Durable Effects Than Firazyr

296590

Oral PHA121 May Lead to Faster, More Durable Effects Than Firazyr

PHA121 (PHA-022121), Pharvaris’ experimental oral therapy for hereditary angioedema (HAE), results in faster, more potent, and more durable suppression of bradykinin-induced changes in blood pressure than injectable Firazyr (icatibant), according to studies in monkeys and healthy volunteers. These findings, along with evidence of PHA121’s favorable pharmacological profile, were recently shared by Anne Lesage, PhD, Pharvaris’ chief early development officer, in an oral presentation at the 12th C1-inhibitor Deficiency and Angioedema Workshop, held virtually, June 3–6.…

You must be logged in to read/download the full post.